

CLINICAL GUIDELINE

Adult Paracetamol Overdose Protocol and Shortened N-acetylcysteine (NAC) Administration Chart

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

| Version Number: | 2 |
|---|--|
| Does this version include changes to clinical advice: | No |
| Date Approved: | 31 October 2022 |
| Date of Next Review: | 11 November 2025 |
| Lead Author: | Andrea Llano & Colin Muir |
| Approval Group: | Medicines Utilisation Subcommittee of ADTC |

Important Note:

The Intranet version of this document is the only version that is maintained. Any printed copies should therefore be viewed as 'Uncontrolled' and as such, may not necessarily contain the latest updates and amendments.




NHSGGC Adult Paracetamol Overdose Protocol and Shortened N-acetylcysteine (NAC) Administration Chart

Contents

| Paracetamol overdose presenting 0–8 hours | page 3 |
|---|------------|
| Paracetamol overdose presenting 8–24 hours | page 4 |
| Paracetamol overdose presenting >24 hours | page 5 |
| Staggered paracetamol overdose | page 6 |
| Therapeutic excess of paracetamol | page 7 |
| Acetylcysteine prescribing and administration chart | pages 8-10 |

Paracetamol overdose presenting 0-8hrs

(Ingested total overdose in ≤1 hour time period)



*** Bloods should be done **2 hours before** the end of infusion 3 and 4.


until: INR ≤1.3, or INR falling on two consecutive bloods
AND INR <3.0

(Bloods should be checked 2 hours before

the end of infusion 4).

Paracetamol overdose presenting 8-24hrs

(Ingested total overdose in ≤1 hour time period)



*Clinical judgement required

If doubt then assume ≥150mg/kg.

**Clinical judgement required


- Ensure no doubt about time of ingestion or type.
- Some patients have a chronically raised ALT/INR.
- Review old LFTs/INRs and if chronic derangement discuss with a senior clinician before proceeding to NAC.
- If ALT newly abnormal despite normal paracetamol concentration, then consider treating.
- Ensure INR is normal, if not consider treating.
- If uncertainty then treat and review.

Blood monitoring

- Checking a paracetamol level 2hrs before the end of bag 2 is NEW for this protocol.
- U&E, HCO3, glu, LFTs, FBC and INR should be done 2hrs before the end of each infusion 2. Ensure results are READY for the end of the infusion.
- If unable to achieve blood sampling at the correct time and a delay of >90 minutes is predicted then proceed to the next infusion to avoid prolonged omission of NAC. Bloods should be checked at the earliest opportunity and discontinuation criteria referred to.
- Capillary Blood Glucose (CBG) 6 hourly while on NAC.
- If rapid or progressive biochemical deterioration then discuss with senior and consider referral to regional transplant centre.
- IV NAC can be associated with minor rise in INR without an acute liver injury.

Paracetamol overdose presenting >24hrs

(Ingested total overdose in ≤1 hour time period)



*Clinical judgement required

- Bedside hepatic toxicity: Jaundice, tender liver, hypoglycaemia, encephalopathy, unexplained lactic acidosis.
- Ensure no doubt about time of ingestion or type.
- If uncertainty then treat and review with bloods.

**Clinical judgement required

- Some patients have a chronically raised ALT/INR.
- Review old LFTs/INRs and if chronic derangement discuss with a senior clinician before proceeding to NAC.

Blood monitoring

- Checking a paracetamol level 2hrs before the end of bag 2 is NEW for this protocol.
- U&E, HCO3, glu, LFTs, FBC and INR should be done 2hrs before the end of each infusion 2.
 Ensure results are READY for the end of the infusion.
- If unable to achieve blood sampling at the correct time and a delay of >90 minutes is predicted then proceed to the next infusion to avoid prolonged omission of NAC. Bloods should be checked at the earliest opportunity and discontinuation criteria referred to.
- Capillary Blood Glucose (CBG) 6 hourly while on NAC.
- If rapid or progressive biochemical deterioration then discuss with senior and consider referral to regional transplant centre.
- IV NAC can be associated with minor rise in INR without an acute liver injury.

*** Bloods should be done **2 hours before** the end of infusion 3 and 4.

Staggered paracetamol overdose

(Ingested total overdose in >1 hour time period in the context of self harm)

START acetylcysteine (NAC) in all patients Take baseline bloods at least 4hrs since last ingestion (U&Es, HCO3, LFTs, FBC, INR, glucose, paracetamol level) Assess for hepatotoxicity (ANY*) 1. Paracetamol level >10mg/L or 2. ALT >50 or 3. INR >1.3 If no features If features of of hepatotoxicity hepatotoxicity then then NAC continue NAC not required Psychiatry liaison referral, see GGC Adult Therapeutics Handbook for local pathway. Referral to be sent by admitting doctor including estimated time to completion of infusion. Take bloods 2hrs before the end of infusion 2: U&Es, HCO3, LFTs, FBC, INR, glucose and paracetamol level Psychiatry liaison referral, see Glasgow Therapeutics Handbook for local pathway Discontinue NAC after infusion 2 if: INR ≤1.3 AND ALT <100 AND ALT <2x admission value AND paracetamol level <20 If criteria for discontinuing Psychiatry review not met then proceed to infusion 3 Discontinue NAC after infusion 3 if: INR ≤1.3 AND ALT <100 AND ALT <2x admission value. (Bloods should be checked 2 hours before the end of infusion 3). If criteria for discontinuing not met then proceed to infusion 4 (and repeat if needed) until: INR ≤1.3, or INR falling on two consecutive bloods AND INR < 3.0 (Bloods should be checked 2 hours before the end of infusion 4).

*Clinical judgement required

- Some patients have a chronically raised ALT/INR.
- Review old LFTs/INRs and if chronic derangement discuss with a senior clinician before proceeding to NAC.

Blood monitoring


- Checking a paracetamol level 2hrs before the end of bag 2 is NEW for this protocol.
- U&E, HCO3, glu, LFTs, FBC and INR should be done 2hrs before the end of each infusion 2. Ensure results are READY for the end of the infusion.
- If unable to achieve blood sampling at the correct time and a delay of >90 minutes is predicted then proceed to the next infusion to avoid prolonged omission of NAC. Bloods should be checked at the earliest opportunity and discontinuation criteria referred to.
- Capillary Blood Glucose (CBG) 6 hourly while on NAC.
- If rapid or progressive biochemical deterioration then discuss with senior and consider referral to regional transplant centre.
- IV NAC can be associated with minor rise in INR without an acute liver injury.

*** Bloods should be done **2 hours before** the end of infusion 3 and 4.

v1.4 November 2020

Therapeutic excess paracetamol overdose

(Ingested total overdose in >1 hour time period with no self harm intent)



*Clinical judgement required

- Bedside hepatic toxicity: Jaundice, tender liver, hypoglycaemia, encephalopathy, unexplained lactic acidosis.
- Ensure no doubt about time of ingestion or type.
- If uncertainty then treat and review with bloods.

**Clinical judgement required

- Ensure no doubt about time of ingestion or type.
- If uncertainty then treat and review with bloods.
- Caution in patients weighing
 <30kg, refer to paediatric regimen on toxbase.

Blood monitoring

- Checking a paracetamol level 2hrs before the end of bag 2 is NEW for this protocol.
- U&E, HCO3, glu, LFTs, FBC and INR should be done 2hrs before the end of each infusion 2. Ensure results are READY for the end of the infusion.
- If unable to achieve blood sampling at the correct time and a delay of >90 minutes is predicted then proceed to the next infusion to avoid prolonged omission of NAC. Bloods should be checked at the earliest opportunity and discontinuation criteria referred to.
- Capillary Blood Glucose (CBG)
 6 hourly while on NAC.
- If rapid or progressive biochemical deterioration then discuss with senior and consider referral to regional transplant centre.
- IV NAC can be associated with minor rise in INR without an acute liver injury.

*** Bloods should be done **2 hours before** the end of infusion 3 and 4.

v1.4 November 2020 7


Adult Acetylcysteine Prescribing and Administration Chart



| Name: | |
|----------|--------------------------|
| Address: | |
| | |
| CHI: | |
| | Affix patient data label |

| Ingestion date & time: |
|--|
| Quantity ingested (mg): |
| Weight (kg): |
| Calculated paracetamol ingested (mg/kg): |
| Baseline serum paracetamol concentration (mg/L): |
| Hours between ingestion & baseline sample: |
| |

Paracetamol overdose treatment nomogram



- If unclear which of the five protocols to follow (pages 3-7), discuss with a senior clinician.
- In situations where paracetamol levels will be used to determine need for acetylcysteine (refer to appropriate protocol), plot the measured plasma concentration (in mg/L) against the time since ingestion. If plasma level falls above the line then give acetylcysteine as detailed below.
- The normogram is less accurate between 15-24 hours and accurate ingestion time is even more vital.
- Please refer to the GGC Adult Therapeutics Handbook and TOXBASE for information on special patient groups. e.g. pregnancy, extremes of weight.
- Reactions to acetylcysteine include flushing, nausea & vomiting. Consider pausing infusion for 30 minutes and symptomatic relief i.e. antiemetic and/or chlorphenamine.
- Hypersensitivity and anaphylactoid reactions with acetylcysteine are not contraindications as the benefit of treatment still outweighs the risk of not treating.
- True anaphylaxis is rare with acetylcysteine but can be managed by stopping the infusion and then restarting at a slower rate.

Table 1. Acetylcysteine IV dosing & administration

| Regimen | First ir | nfusion | Second (& extended) infusion | | | |
|----------------------|------------------------|--|--|-------------------------|--|--|
| Infusion fluid | 200mL sodium chlorid | e 0.9% or 5% glucose | 1000mL sodium chloride 0.9% or 5% glucose | | | |
| Preparation | | pag and remove 50mL ume of acetylcysteine | Add required volume of acetylcysteine to 1000mL infusion bag | | | |
| Duration of infusion | 2 h | ours | 10 hours | | | |
| Drug dose | 100mg/kg a | cetylcysteine | 200mg/kg a | cetylcysteine | | |
| Weight (kg) | Ampoule volume (mL) | Infusion rate (mL/h) | Ampoule volume (mL) | Infusion rate (mL/h) | | |
| 30-39 | 18 | 109 | 35 | 104 | | |
| 40-49 | 23 112 | | 45 | 105 | | |
| 50-59 | 28 | 114 | 55 | 106 | | |
| 60-69 | 33 | 117 | 65 | 107 | | |
| 70-79 | 38 | 119 | 75 | 108 | | |
| 80-89 | 43 | 122 | 85 | 109 | | |
| 90-99 | 48 | 124 | 95 | 110 | | |
| 100-109 | 53 | 127 | 105 | 111 | | |
| ≥ 110 | 55 | 128 | 110 | 111 | | |

Each ampoule = 200mg/mL acetylcysteine. Dose calculation based on weight in middle of band. Ampoule rounded up to nearest whole number.

Adult Acetylcysteine Prescribing and Administration Chart

Please ensure that acetylcysteine is also prescribed on the patient's Kardex.

| Name: | | |
|-------|--------------------------|--|
| | | |
| DoB: | | |
| CHI: | | |
| | Affix patient data label | |

| Infusion 1 Acetylcysteine 10 | | | ysteine 100 |)mg/kg ov | er 2 hours | | | | | |
|------------------------------|--------------|--------------|--------------------|-----------------------------|---------------------------|----------------------------|--------------|-----------------------------|---------------------------|---------------|
| Prescrip | Prescription | | | | | Preparation | Admini | stration checl | S | |
| Date | Time | Dose (mL) | Diluent (200mL) | Infusion rate (mL/hr) | Prescriber's signature | Prepared/ Checked by | Date Time | Volume remaining (mL) | Volume infused (mL) | Checked by |
| | | | | | | | | | | |
| Comm | ents: | | | Stopped by: | | | | | | |
| | | | | Date: | Time | Signature | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |

| Infusion 2 Acet | | ysteine 200 | mg/kg ove | er 10 hours | | | | | |
|-----------------|--------------|---------------------|-----------------------------|---|--|--|---|--|--|
| tion | | | | | Preparation | Administration checks | | | |
| Time | Dose (mL) | Diluent (1000mL) | Infusion rate (mL/hr) | Prescriber's signature | Prepared/ Checked by | Date Time | Volume remaining (mL) | Volume infused (mL) | Checked by |
| ents: | | | Stopped | by: | | | | | |
| | | | Date: | Time | Signature | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | tion Time | Time Dose (mL) | Time Dose Diluent (1000mL) | Time Dose Diluent (nL) (1000mL) rate (mL/hr) ents: Stopped | Time Dose (mL) (1000mL) Infusion rate (mL/hr) signature Stopped by: | Time Dose (mL) (1000mL) Infusion rate (mL/hr) Prescriber's signature Checked by Stopped by: | Time Dose (mL) (1000mL) Infusion rate (mL/hr) Stopped by: Stopped by: Preparation Administration Prescriber's signature Checked by Stopped by: | Time Dose (mL) (1000mL) Infusion rate (mL/hr) Stopped by: Preparation Administration check Prepared/ Checked by (mL) Stopped by: | Time Dose (mL) Cloud (mL) Infusion rate (mL/hr) Prescriber's signature (mL/hr) Checked by Checked (mL) Stopped by: |

Extended treatment

If extended treatment with acetylcysteine is required (see guideline section), continue at the dose and infusion rate used for the second infusion and prescribe on page 10.

Recheck U&Es, bicarbonate, LFTs, FBC and INR 2 hours before the end of infusions 3 and 4 to assess the need to continue.

Refer to appropriate protocol regarding discontinuation of extended treatment

Adult Acetylcysteine Prescribing and **Administration Chart**

| Name: | | |
|----------|--------------------------|--|
| Address: | | |
| DoB: | | |
| CHI: | | |
| | Affix patient data label | |

| Infusion 3* (extended treatment) Prescription Date Time | | Acetylo | ysteine 200 Diluent | mg/kg ove | er 10 hours Prescriber's | Preparation Prepared/ | Adminis Date | stration checl | ks Volume | Checked |
|---|------|---------|---------------------|-----------------|---------------------------|-----------------------|-----------------|-------------------|-----------------|---------|
| Dute | Time | (mL) | (1000mL) | rate (mL/hr) | signature | Checked by | Time | remaining (mL) | infused (mL) | by |
| | | | | | | | | | | |
| Comments: | | | Stopped by: | | | | | | | |
| | | | Date: | Time | Signature | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |

| Infusion 4* (extended treatment) | | Acetylo | ysteine 200 | mg/kg ove | er 10 hours | | | | | |
|---|-----------|--------------|---------------------|-----------------------------|---------------------------|----------------------------|--------------|-----------------------------|---------------------------|---------------|
| Prescrip | tion | | | | | Preparation | Adminis | stration checl | KS | |
| Date | Time | Dose (mL) | Diluent (1000mL) | Infusion rate (mL/hr) | Prescriber's signature | Prepared/ Checked by | Date Time | Volume remaining (mL) | Volume infused (mL) | Checked by |
| | | | | | | | | | | |
| Comments: | | | Stopped by: | | | | | | | |
| | | | Date: | Time | Signature | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| *These infusions should only be commenced if extended | | | | | | | | | | |
| treatmer | nt is req | uired. Ple | | protocols (| page 3-7) to | | | | | |
| | | | | | | l | | | 1 | |

If the patient meets criteria for a further infusion then repeat infusions 3 and/or 4 (extended). Refer to protocols for discontinuation criteria. Prescribe a 5th infusion using a new chart, contacting pharmacy for advice if required.